What Is the Bundibugyo Strain of Ebola and Why Is It Different
Published 10 July 2026
The 2026 Ebola outbreak is a different strain with no approved vaccine. Here is what makes the Bundibugyo virus different from the 2014 outbreak, and why that matters.
Not All Ebola Outbreaks Are the Same
When most people hear "Ebola," they picture the 2014 to 2016 West African outbreak, which devastated Guinea, Liberia, and Sierra Leone and reached Nigeria through a single traveller. That outbreak was caused by the Zaire ebolavirus. The outbreak currently spreading through the Democratic Republic of Congo and Uganda, declared a Public Health Emergency of International Concern by the WHO on 17 May 2026, is caused by a different species entirely: the Bundibugyo virus, or BDBV. That distinction matters far more than it might sound.
Why the Species Matters So Much
Ebola is not a single virus. It is a group of related viruses, or species, that cause similar disease but differ in important ways, including transmissibility and severity. Previous outbreaks of Bundibugyo virus, one in Uganda's Bundibugyo District in 2007 to 2008, from which the virus gets its name, and another in Isiro, DRC, in 2012, suggested lower transmissibility and a lower case fatality ratio than the Zaire species, with estimated reproduction numbers ranging from 1.2 to 2.6.
But lower historical severity does not mean this outbreak is manageable with existing tools. The vaccines developed and approved after the 2014 to 2016 outbreak, including rVSV-ZEBOV, were certified specifically against the Zaire ebolavirus. They are not certified as effective against Bundibugyo virus. This means the global health response is essentially starting without a proven vaccine for this specific strain, even though Ebola vaccines exist in general.
What Is Being Done About the Vaccine Gap
The Coalition for Epidemic Preparedness Innovations, known as CEPI, announced funding on 1 June 2026 to fast-track three vaccine candidates specifically targeting this strain. IAVI received $3.2 million, Moderna received $50 million, and the University of Oxford received $8.6 million. The WHO-sponsored PARTNERS clinical trial protocol is being deployed across the DRC and Uganda to test these and other promising treatments and vaccines in real time as the outbreak continues.
Until one of these candidates is validated and deployed at scale, the primary tools available are early detection, isolation, supportive care, and strict infection prevention and control measures, the same fundamentals that proved effective in containing previous outbreaks before vaccines existed at all.
Diagnosing the Right Strain Matters Too
The Africa Centres for Disease Control and Prevention recommended on 22 May 2026 that diagnosis for this outbreak rely on real-time PCR molecular testing rather than rapid antigen tests, because no currently available rapid diagnostic test meets the WHO's target product profile specifications for detecting this particular strain. This is a meaningful operational detail: a hospital relying on a standard rapid test kit designed for the Zaire strain could potentially miss or delay diagnosis of a Bundibugyo case, which is part of why laboratory capacity and trained personnel matter as much as the test kits themselves.
How Big Is the Current Outbreak
By 24 May 2026, the DRC had reported 906 suspected cases, with 105 confirmed and ten confirmed deaths across three provinces. Uganda reported seven confirmed cases, including three imported and four locally acquired, with a case fatality ratio of 14% in that country specifically. By late June, cumulative confirmed deaths in the DRC had risen to 321, with two deaths recorded in Uganda. Early infections are believed to have occurred as far back as February 2026 in the town of Mongbwalu, with the outbreak only being formally identified and declared in mid-May, a gap that gave the virus weeks to spread before the global response began.
Why This Context Matters If You Live in Nigeria
Understanding which strain is circulating helps explain why Nigeria's preparedness advisories have emphasised clinical suspicion and travel history over reassurance that existing vaccines would handle a case if one appeared. There is currently no vaccine safety net for this specific virus, which makes early recognition and isolation the most important tools available, both globally and within Nigeria's own health system.
If you are concerned about symptoms following travel to or contact with someone from an affected region, knowing which hospitals near you have isolation capacity and infection control protocols in place matters more than usual in an outbreak without a vaccine to fall back on.
Medicall's verified healthcare directory can help you find hospitals near you equipped for infectious disease isolation and care.
Find a hospital with isolation capacity near you on Medicall.
Frequently Asked Questions
What is the Bundibugyo virus?
The Bundibugyo virus is one of several species within the Ebola virus group, distinct from the Zaire ebolavirus responsible for the 2014 to 2016 West African outbreak. It was first identified during an outbreak in Uganda's Bundibugyo District in 2007 to 2008.
Is there a vaccine for the Bundibugyo virus?
Not currently approved for general use. Existing Ebola vaccines were developed and certified against the Zaire ebolavirus species and are not certified as effective against Bundibugyo virus. The Coalition for Epidemic Preparedness Innovations is fast-tracking three new vaccine candidates specifically for this strain as of June 2026.
How is the 2026 Bundibugyo outbreak being diagnosed?
The Africa Centres for Disease Control and Prevention recommends real-time PCR molecular testing for confirming Bundibugyo virus infection, since no rapid antigen diagnostic test currently meets the accuracy standards required for this specific strain.
Is the Bundibugyo virus more or less severe than other Ebola strains?
Historical data from previous Bundibugyo outbreaks suggests lower transmissibility and case fatality compared to the Zaire ebolavirus species. However, the lack of an approved vaccine for this strain means the current outbreak still requires aggressive supportive care and strict containment measures.
How many cases has the 2026 Bundibugyo outbreak caused?
By late June 2026, the outbreak had caused 321 confirmed deaths in the Democratic Republic of Congo and two in Uganda, with cases also reported in additional countries through travel-related transmission.